News
Storm reveals STC-15 data for patients with acute myeloid leukaemia
Storm Therapeutics– a company focusing on ribonucleic acid modifying enzymes (RMEs) for oncology – has presented new data on its candidate, the METTL3 inhibitor, STC-15.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Storm Therapeutics– a company focusing on ribonucleic acid modifying enzymes (RMEs) for oncology – has presented new data on its candidate, the METTL3 inhibitor, STC-15.